Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
AUTOR(ES)
Raftery, James
FONTE
BMJ Group
RESUMO
Two new drugs provide startling benefits in the treatment of age‐related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was compared to that of bevacizumab (Avastin), which costs up to 100 times less. A cost effectiveness model was developed to assess the cost per quality adjusted life year (QALY) over 10 years. For predominantly classic AMD, the efficacy of bevacizumab relative to ranibizumab would have to be around 40% for the latter to achieve £30k per QALY, a NICE threshold. Similar but worse results applied to the other main forms of AMD, minimally occult and occult with no classic lesions. The price of ranibizumab would have to be drastically reduced for it to be cost effective. Continued unlicensed use of bevacizumab raises ethical, legal and policy questions. Public pressure may be the most potent weapon in persuading Genentech to license bevacizumab for AMD.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1954941Documentos Relacionados
- Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)
- Coronary heart disease prevention: insights from modelling incremental cost effectiveness
- Coronary heart disease prevention: insights from modelling incremental cost effectiveness
- Non‐responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions
- Uso do bevacizumab (Avastin®) na síndrome KID: relato de caso